Literature DB >> 29854250

Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and OAE-based representation and analysis of adverse events in patients treated with cancer drugs.

Mei U Wong1, Rebecca Racz1,2, Edison Ong1, Yongqun He1.   

Abstract

A critical issue in the usage of cancer drugs is its association with various adverse events (AEs) in some, but not all, patients. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) is a controlled terminology for AE classification and analysis in cancer clinical trials. The Ontology of Adverse Events (OAE) is a community-based ontology in the domain of AEs. In this study, OAE was first updated by including AE severity grading and OAE-CTCAE mapping. An OAE subset containing CTCAE-related terms and their associated OAE terms was generated to facilitate term usage. A use case study based on a published cancer drug clinical trial demonstrates that OAE provides better hierarchical representation, includes semantic relations, and supports automated reasoning. Demonstrated with a single patient analysis, the OAE framework supports precision informatics for representing AEs and related genetic and clinical conditions in individual patients treated with cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29854250      PMCID: PMC5977606     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  18 in total

1.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

2.  Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.

Authors:  Sirarat Sarntivijai; Zuoshuang Xiang; Kerby A Shedden; Howard Markel; Gilbert S Omenn; Brian D Athey; Yongqun He
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

3.  Disease Ontology: a backbone for disease semantic integration.

Authors:  Lynn Marie Schriml; Cesar Arze; Suvarna Nadendla; Yu-Wei Wayne Chang; Mark Mazaitis; Victor Felix; Gang Feng; Warren Alden Kibbe
Journal:  Nucleic Acids Res       Date:  2011-11-12       Impact factor: 16.971

4.  Uberon, an integrative multi-species anatomy ontology.

Authors:  Christopher J Mungall; Carlo Torniai; Georgios V Gkoutos; Suzanna E Lewis; Melissa A Haendel
Journal:  Genome Biol       Date:  2012-01-31       Impact factor: 13.583

5.  A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.

Authors:  Munetaka Takekuma; Kwong K Wong; Robert L Coleman
Journal:  Gynecol Oncol Res Pract       Date:  2016-05-05

6.  Ontobee: A linked ontology data server to support ontology term dereferencing, linkage, query and integration.

Authors:  Edison Ong; Zuoshuang Xiang; Bin Zhao; Yue Liu; Yu Lin; Jie Zheng; Chris Mungall; Mélanie Courtot; Alan Ruttenberg; Yongqun He
Journal:  Nucleic Acids Res       Date:  2016-10-12       Impact factor: 16.971

7.  Building a drug ontology based on RxNorm and other sources.

Authors:  Josh Hanna; Eric Joseph; Mathias Brochhausen; William R Hogan
Journal:  J Biomed Semantics       Date:  2013-12-18

8.  OAE: The Ontology of Adverse Events.

Authors:  Yongqun He; Sirarat Sarntivijai; Yu Lin; Zuoshuang Xiang; Abra Guo; Shelley Zhang; Desikan Jagannathan; Luca Toldo; Cui Tao; Barry Smith
Journal:  J Biomed Semantics       Date:  2014-07-05

9.  The Ontology for Biomedical Investigations.

Authors:  Anita Bandrowski; Ryan Brinkman; Mathias Brochhausen; Matthew H Brush; Bill Bug; Marcus C Chibucos; Kevin Clancy; Mélanie Courtot; Dirk Derom; Michel Dumontier; Liju Fan; Jennifer Fostel; Gilberto Fragoso; Frank Gibson; Alejandra Gonzalez-Beltran; Melissa A Haendel; Yongqun He; Mervi Heiskanen; Tina Hernandez-Boussard; Mark Jensen; Yu Lin; Allyson L Lister; Phillip Lord; James Malone; Elisabetta Manduchi; Monnie McGee; Norman Morrison; James A Overton; Helen Parkinson; Bjoern Peters; Philippe Rocca-Serra; Alan Ruttenberg; Susanna-Assunta Sansone; Richard H Scheuermann; Daniel Schober; Barry Smith; Larisa N Soldatova; Christian J Stoeckert; Chris F Taylor; Carlo Torniai; Jessica A Turner; Randi Vita; Patricia L Whetzel; Jie Zheng
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

10.  Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases.

Authors:  Jiangan Xie; Lili Zhao; Shangbo Zhou; Yongqun He
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

View more
  4 in total

1.  Artificial Intelligence in Pharmacovigilance: An Introduction to Terms, Concepts, Applications, and Limitations.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2022-05-17       Impact factor: 5.606

2.  COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning.

Authors:  Anthony Huffman; Edison Ong; Junguk Hur; Adonis D'Mello; Hervé Tettelin; Yongqun He
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

3.  ODAE: Ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions.

Authors:  Hong Yu; Solomiya Nysak; Noemi Garg; Edison Ong; Xianwei Ye; Xiangyan Zhang; Yongqun He
Journal:  BMC Bioinformatics       Date:  2019-05-01       Impact factor: 3.169

4.  Ontology-Based Classification and Analysis of Adverse Events Associated With the Usage of Chloroquine and Hydroxychloroquine.

Authors:  Jamie Ngai; Madison Kalter; James Brian Byrd; Rebecca Racz; Yongqun He
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.